Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

SURMOUNT-OSA

Eli Lilly · Phase 3 · Completed · Enrollment 469

NCT05412004

EudraCT 2021-004552-41

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Tirzepatide MTD_GPI1n/rn/rn/rn/r
Placebo_GPI1n/rn/rn/rn/r
Tirzepatide MTD_GPI2n/rn/rn/rn/r
Placebo_GPI2n/rn/rn/rn/r

Not shown

  • Tirzepatide MTD_GPI1: endpoint not reported
  • Placebo_GPI1: endpoint not reported
  • Tirzepatide MTD_GPI2: endpoint not reported
  • Placebo_GPI2: endpoint not reported